- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.01. | EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India | ||
| 27.01. | Servier delivers 16% revenue jump, firming up €10B ambition by 2030 | ||
| 27.01. | Pfizer retains top spot in vaccine rankings as Sanofi's slide sparks 'code red' call | ||
| 27.01. | Siegfried extends M&A streak, gaining 3 sites from SK Capital and advancing US onshoring aims | ||
| 26.01. | Catalent moves to wind down operations at EU cell therapy manufacturing hub | ||
| 26.01. | New rules, higher stakes: Biopharma plays the long game in 2026 | ||
| 26.01. | Arcutis, Kowa part ways on US marketing partnership for Zoryve | ||
| 26.01. | Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance | ||
| 26.01. | Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs | ||
| 23.01. | Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials | ||
| 23.01. | ST Pharm inks $56M deal to produce API for a US biotech | ||
| 23.01. | Lilly battles weight stigma in short film centering obesity conversation on health, not appearance | ||
| 23.01. | RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio shot guidance on podcast | ||
| 23.01. | Novo's Wegovy pill launch wows with strong early uptake: analysts | ||
| 23.01. | Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure | ||
| 23.01. | Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster | ||
| 22.01. | Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report | ||
| 22.01. | Invivyd teams up with Olympic skier Lindsey Vonn for antibody education | ||
| 22.01. | CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Biosciences and others | ||
| 22.01. | Lundbeck 'not willing to compromise' on M&A strategy after missed Avadel attempt: exec | ||
| 22.01. | Trump's Davos drug pricing claims decried as 'fake news' by French presidency | ||
| 22.01. | Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold | ||
| 21.01. | In J&J talc litigation, N.J. court-appointed official recommends allowing expert testimony | ||
| 21.01. | Led by Darzalex surge, J&J expects revenue to reach $100B in 2026 | ||
| 21.01. | IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.